Idorsia Pharmaceuticals Ltd: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy

Allschwil, Switzerland - March 10, 2022 Idorsia Ltd (SIX: IDIA) today announced that new data for daridorexant in patients with insomnia disorder, including long-term safety and efficacy data, will

Related Keywords

Canada ,Italy ,United States ,Rome ,Lazio ,Allschwil ,Switzerland General ,Switzerland ,Berlin ,Germany ,American ,Swiss ,Andrewc Weiss ,Cliffordb Saper ,Antonio Olivieri ,J Clin Pharmacol ,Dieter Kunz ,Idorsia Ltd ,American Psychiatric Association ,Head Of Investor Relations Corporate Communications ,Drug Administration ,Swiss Exchange ,Head Of Global Medical Affairs Idorsia ,University Of Pittsburg ,European Medicines Agency ,Idorsia Pharmaceuticals Ltd ,Health Canada ,Scientific Program For World ,Committee For Medicinal Products Human Use ,World Sleep ,Senior Vice President ,Global Medical Affairs ,Scientific Program ,Insomnia Daytime Symptoms ,Impacts Questionnaire ,Lancet Neurology ,Medicinal Products ,Human Use ,Statistical Manual ,Mental Disorders ,Discov Today Dis ,Statistics Canada ,Clin Sleep ,Idorsia Pharmaceuticals ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,Idorsia ,Pharmaceuticals ,Data ,Daridorexant ,Patients ,Insomnia ,Disorder ,Ncluding ,Song ,Term ,Safety ,Efficacy ,Resented ,World ,Sleep ,022 ,